Total intravenous anesthesia with remifentanil and propofol for implantation of cardioverter-defibrillators in patients with severely reduced left ventricular function

被引:39
作者
Lehmann, A
Boldt, J
Zeitler, C
Thaler, E
Werling, C
机构
[1] Klinikum Stadt Ludwigshafen, Dept Anesthesiol & Intens Care Med, D-67063 Ludwigshafen, Germany
[2] Klinikum Stadt Ludwigshafen, Dept Cardiac Surg, D-6700 Ludwigshafen, Germany
关键词
TIVA; propofol; remifentanil; left ventricular dysfunction; cardioverter-defibrillator;
D O I
10.1016/S1053-0770(99)90166-0
中图分类号
R614 [麻醉学];
学科分类号
100217 [麻醉学];
摘要
Objective: To determine the cardiocirculatory effects of total intravenous anesthesia (TIVA) using remifentanil and propofol in high-risk cardiac surgical patients. Design: Prospective study of 20 patients undergoing first-time implantation of a cardioverter-defibrillator (ICD). Setting: Major, community, university-affiliate hospital. Participants and Interventions: In 20 patients with severely reduced left ventricular function (left ventricular ejection fraction <30%) undergoing first-time implantation of an ICD, TIVA using remifentanil and propofol was performed. Measurements and Main Results: Extensive hemodynamic monitoring using a pulmonary artery catheter was performed: (T1) before induction of anesthesia, (T2) after intubation, (T3) after skin incision, (T4) after first defibrillation, and (T5) 10 minutes after extubation. Propofol, 3.0 @ 0.6 mg/kg/h (range, 1.9 to 4.4 mg/kg/h), and remifentanil, 0.30 +/- 0.05 mu g/kg/min (range, 0.21 to 0.40 mu g/kg/min), were used. Total costs added up to US $44.60 per patient. Patients could be extubated within 12.5 +/- 4.2 minutes after stopping anesthesia. There were significant decreases in heart rate (HR: from 77 +/- 12 to 57 +/- 10 beats/min [T3]), mean arterial blood pressure (MAP; from 98 +/- 14 to 70 +/- 12 mmHg [T2]) and systemic vascular resistance (from 1,551 +/- 309 to 1,233 +/- 274 dyne . s . cm(-5) [T2]). Cardiac index (CI) slightly decreased only at T3 (from 2.46+/-0.42 to 1.92+/-0.29 L/min/m(2): p = 0.04). The decrease in MAP could easily be treated by volume infusion in most patients (17 patients). Sixty-five percent of the patients needed dobutamine to increase CI to greater than 2.0 L/min/m(2) (mean dose, 2.2 +/- 1.8 mu g/kg/min). Dobutamine could be stopped before extubation in all patients. No patient needed sustained inotropic or ventilatory support and intensive care therapy could be avoided. Conclusion: TIVA using remifentanil and propofol in patients with severely reduced left ventricular function is safe, well-controllable, and allows early extubation after implantation of an ICD. Because patients without complications did not need a postoperative intensive care stay, costs may be considerably reduced. Copyright (C) 1999 by W.B. Saunders Company.
引用
收藏
页码:15 / 19
页数:5
相关论文
共 34 条
[1]
IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR - EVALUATION OF CLINICAL NEUROLOGIC OUTCOME AND ELECTROENCEPHALOGRAPHIC CHANGES DURING IMPLANTATION [J].
ADAMS, DC ;
HEYER, EJ ;
EMERSON, RG ;
SPOTNITZ, HM ;
DELPHIN, E ;
TURNER, C ;
BERMAN, MF .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1995, 109 (03) :565-573
[2]
NONTHORACOTOMY LEAD SYSTEM FOR IMPLANTABLE DEFIBRILLATOR [J].
BLAKEMAN, BP ;
SULLIVAN, HJ ;
MONTOYA, A ;
CALANDRA, D ;
WILBER, D ;
OLSHANSKY, B ;
KALL, J ;
KOPP, D ;
PIFARRE, R .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1993, 106 (06) :1040-1047
[3]
Transition to post-operative epidural or patient-controlled intravenous analgesia following total intravenous anaesthesia with remifentanil and propofol for abdominal surgery [J].
Bowdle, TA ;
Ready, LB ;
Kharasch, ED ;
Nichols, WW ;
Cox, K .
EUROPEAN JOURNAL OF ANAESTHESIOLOGY, 1997, 14 (04) :374-379
[4]
Early extubation after mitral valve surgery: A target-controlled infusion of propofol and low-dose sufentanil [J].
DAttellis, N ;
NicolasRobin, A ;
Delayance, S ;
Carpentier, A ;
Baron, JF .
JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 1997, 11 (04) :467-473
[5]
DeMulder PA, 1997, LAB ANIM SCI, V47, P367
[6]
INITIAL CLINICAL-EXPERIENCE WITH REMIFENTANIL, A NEW OPIOID METABOLIZED BY ESTERASES [J].
DERSHWITZ, M ;
RANDEL, GI ;
ROSOW, CE ;
FRAGEN, RJ ;
CONNORS, PM ;
LIBROJO, ES ;
SHAW, DL ;
PENG, AW ;
JAMERSON, BD .
ANESTHESIA AND ANALGESIA, 1995, 81 (03) :619-623
[7]
REMIFENTANIL PHARMACOKINETICS AND PHARMACODYNAMICS - A PRELIMINARY APPRAISAL [J].
EGAN, TD .
CLINICAL PHARMACOKINETICS, 1995, 29 (02) :80-94
[8]
ELECTROPHYSIOLOGICAL LABORATORY, ELECTROPHYSIOLOGIST-IMPLANTED, NONTHORACOTOMY-IMPLANTABLE CARDIOVERTER/DEFIBRILLATORS [J].
FITZPATRICK, AP ;
LESH, MD ;
EPSTEIN, LM ;
LEE, RJ ;
SIU, A ;
MERRICK, S ;
GRIFFIN, JC ;
SCHEINMAN, MM .
CIRCULATION, 1994, 89 (06) :2503-2508
[9]
INITIAL EXPERIENCE WITH TRANSVENOUS IMPLANTABLE CARDIOVERTER DEFIBRILLATOR LEAD SYSTEMS - OPERATIVE MORBIDITY AND MORTALITY [J].
FRAME, R ;
BRODMAN, R ;
GROSS, J ;
HOLLINGER, I ;
FISHER, JD ;
KIM, SG ;
FERRICK, K ;
ROTH, J ;
FURMAN, S .
PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 1993, 16 (01) :149-152
[10]
REMIFENTANIL - A NEW OPIOID [J].
GLASS, PSA .
JOURNAL OF CLINICAL ANESTHESIA, 1995, 7 (07) :558-563